Market News & Trends
AbbVie Announces FDA & EMA Updates for Epcoritamab for the Treatment of Relapsed/Refractory Follicular Lymphoma
AbbVie recently announced updates from the US FDA and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed…
Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 & ELAINE-2 Trial Results
Sermonix Pharmaceuticals Inc. recently announced results of its two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies were published in Annals of Oncology,…
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control & Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells
Sana Biotechnology, Inc. recently announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP)…
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial
TILT Biotherapeutics recently presented safety and efficacy data from its international Phase 1 trial in patients with metastatic melanoma (NTC04217473), in an oral presentation at…
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen & Ultevursen Ophthalmic Assets
Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU….
Rigel Pharmaceuticals & MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML & Other Cancers
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center (MD Anderson) recently announced a multi-year strategic development collaboration to expand the evaluation…
IMIDomics & Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research & Development
IMIDomics recently announced it is expanding its strategic collaboration with Bristol Myers Squibb that extends the existing relationship between the two companies, advancing their shared commitment to….
ONK Therapeutics & NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies & FLEX-NK Bispecific Antibodies
ONK Therapeutics and NAYA Biosciences Inc. announced they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally engineered natural….
Incannex Provides Update on Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently provided the following update on its proprietary IHL-42X drug candidate. Obstructive sleep apnea (OSA) is characterized by a narrowing or obstruction…
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting With FDA for Rosacea Treatment
Journey Medical Corporation recently announced it received the official meeting minutes from its pre-New Drug Application (NDA) meeting with the FDA for DFD-29 (Minocycline Hydrochloride…
Vetter Joins Science Based Targets Initiative (SBTi)
Vetter has recently joined the Science Based Targets Initiative (SBTi) membership group as of November 2023. The goal of the companies in the SBTi is…
Recipharm Announces Collaboration With Oz-UK to Accelerate the Development of Low Global Warming Potential pMDIs Utilizing HFA-152a Propellant
Recipharm recently announced a collaboration with Oz-UK to accelerate the development and manufacture of “green” pressurized metered dose inhalers (pMDIs). The pMDIs will utilize valves…
Curia Recognized on India Pharma Outlook’s 2023 List of Top 10 CDMO Companies in India
Curia recently announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be…
Rumi Scientific Announces Partnership With X-Chem for Development of Lead Candidate in Huntington’s Disease
Rumi Scientific recently announced it has entered into a partnership with X-Chem through which X-Chem will develop a lead candidate BRD9 inhibitor for the treatment…
Colorcon Unveils Corelease - A Unified Brand for Novel Controlled-Release Formulated Systems
Ready formulated systems approach simplifies the development and manufacturing for controlled release…..
Ocean Biomedical Announces Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
Ocean Biomedical, Inc. recently announced its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of….
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab With New US Patent Issuance
Checkpoint Therapeutics, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued a new patent (US Patent No. 11,834,505) covering a method of…
Oxford Biomedica Signs Agreement to Acquire ABL Europe, Consolidating Position as a Global Pure-Play CDMO
Oxford Biomedica plc recently announced it has entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Mérieux SA, for the acquisition of….
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
GT Biopharma, Inc. recently announced the submission of an Investigational New Drug (IND) application with the US FDA for the development of GTB-3650, a 2nd…
